CD274 and malignant mesothelioma: ICI therapy is also thought to have a biologically attractive potential benefit for malignant mesothelioma based on the pathogenic inflammatory microenvironment and programmed cell death ligand 1 (PD-L1) expression identified in 14–59% of tumors.